key: cord-0914563-behdibtb
authors: Prabhakara, Chaitra; Godbole, Rashmi; Sil, Parijat; Jahnavi, Sowmya; van Zanten, Thomas S; Sheth, Dhruv; Subhash, Neeraja; Chandra, Anchal; Nuthakki, Vijay Kumar; Puthiyapurayil, Theja Parassini; Ahmed, Riyaz; Najar, Ashaq Hussain; Lingamallu, Sai Manoz; Das, Snigdhadev; Mahajan, Bhagyashri; Vemula, Praveen; Bharate, Sandip B; Singh, Parvinder Pal; Vishwakarma, Ram; Guha, Arjun; Sundaramurthy, Varadharajan; Mayor, Satyajit
title: Niclosamide inhibits SARS-CoV2 entry by blocking internalization through pH-dependent CLIC/GEEC endocytic pathway
date: 2020-12-16
journal: bioRxiv
DOI: 10.1101/2020.12.16.422529
sha: 54a977a791b7638f5ba7b4d1a08e7cd4d00ca7a4
doc_id: 914563
cord_uid: behdibtb

Many viruses utilize the host endo-lysosomal network to infect cells. Tracing the endocytic itinerary of SARS-CoV2 can provide insights into viral trafficking and aid in designing new therapeutic targets. Here, we demonstrate that the receptor binding domain (RBD) of SARS-CoV2 is internalized via the clathrin and dynamin-independent, pH-dependent CLIC/GEEC (CG) endocytic pathway. Endosomal acidification inhibitors like BafilomycinA1 and NH4Cl, which inhibit the CG pathway, strongly block the uptake of RBD. Using transduction assays with SARS-CoV2 Spike-pseudovirus, we confirmed that these acidification inhibitors also impede viral infection. By contrast, Chloroquine neither affects RBD uptake nor extensively alters the endosomal pH, yet attenuates Spike-pseudovirus entry, indicating a pH-independent mechanism of intervention. We screened a subset of FDA-approved acidification inhibitors and found Niclosamide to be a potential SARS-CoV2 entry inhibitor. Niclosamide, thus, could provide broader applicability in subverting infection of similar category viruses entering host cells via this pH-dependent endocytic pathway.

process. A search for antivirals affecting the endocytic entry of viruses is particularly exciting as 23 infections from multiple related viruses can be controlled through the inhibition of a common step. 24 Virus entry into host cells is a multistep process. A key step in successful invasion is the release of viral 25 genomic content into the host cell cytoplasm. To achieve this, viruses bind to specific cell surface 26 receptors and subsequently undergo membrane fusion either directly at the plasma membrane or 27 following endocytic uptake. While fusion directly at the plasma membrane is well established for HIV 28 and Influenza virus infections 4,5 , both alternatives of entry are feasible for CoV infections depending 29 on the availability of receptors and proteases at the host cell surface. Different CoVs interact with a 30 range of specific receptors for entry. For instance, CoV 229E binds to CD13 (aminopeptidase N) 6 , 31 CoVs OC43 and HKU1 recognize 9-O-acetylated sialic acids 7 , MERS uses DPP4/CD26 8 and CoVs 32 4 86 We employed the methodology of tracking RBD uptake along with cargoes specific to CME 87 (transferrin) and CG (10kDa dextran) endocytic pathway to determine the endocytic route taken up by 88 RBD ( Figure 1A ). AGS cells without overexpression of ACE2 also support RBD uptake suggesting 89 that there is sufficient endogenous receptor expressed in these cells. At 10 minutes post internalization, 90 transferrin endosomes of the CME pathway are distinct from dextran endosomes of the CG pathway. 91 At these times, internalized RBD is colocalized with endosomes containing the CG cargo but not the 92 CME cargo ( Figure S2A , S2B). At 30 minutes post internalization, as well, this segregation remains. 93 While a small fraction of RBD endosomes were colocalized with endosomes containing both transferrin 94 and dextran, a large fraction of RBD endosomes were localized to compartments uniquely marked by 95 dextran ( Figure 1B, 1C ; compare % RBD with transferrin and dextran). This suggests that the itinerary 96 of uptake of RBD is similar to CG cargo and different from CME cargo. 97 Towards determining the trafficking route of RBD, we examined the effect of inhibitors of CG pathway 98 on RBD, dextran and transferrin uptake in AGS cells. Cells were subjected to a brief pre-treatment with 99 different inhibitors (30 minutes), followed by a pulse of RBD, dextran and transferrin (30 minutes) in 100 the presence of these inhibitors (Methods). CG pathway is regulated by small GTPases -CDC42 43 , 101 Arf1 44 and GEF of Arf1, GBF1 45 . Inhibitors that block the function of these regulators affect the 102 formation of CG endosomes without altering uptake through the CME pathway. The inhibitor AN96, 103 which is a stable analog of LG-186 46,47 , targets GBF1 and specifically affects the CG pathway (Godbole 104 et al., Manuscript in preparation). We observed that AN96 treatment reduced both RBD and dextran 105 uptake but had minimal effects on the amount of transferrin internalized ( Figure 1D , 1E). We also 106 observed that the peri-nuclear transferrin recycling endosomal pool was redistributed throughout the 107 cytoplasm upon treatment with AN96 without affecting the net amount of transferrin internalized. 108 Another CG pathway inhibitor, ML141 (CDC42 inhibitor) 47 , also significantly decreased both dextran 109 as well as RBD uptake ( Figure S2E , S2F). 110 Blocking of the CG pathway often results in the redistribution of CG cargo towards CME pathway 42 . 111 Therefore, using high-resolution imaging, we assessed the fate of the RBD endosomes that continued 112 to be internalized upon treatment with AN96. We observed that an increased fraction of internalized 113 RBD endosomes colocalized with transferrin in AN96 treated cells compared to that of control ( Figure   114 S2C, S2D(i)). Similarly, increased co-occurrence was observed in the fraction of dextran endosomes 115 associated with transferrin endosomes on comparing the control with AN96 treated cells ( Figure   116 S2D(iii)). Blocking the CG pathway results in altered trafficking itinerary of RBD and increases its 117 association with transferrin. This suggests that RBD could be redirected to be internalized via the CME 118 upon blocking the CG pathway. 119 Since 10kDa dextran marks both CG cargo as well as larger endocytic compartments like those derived 120 from macropinocytosis 48 , we tested if macropinocytosis plays any role in RBD uptake. Several viruses 121 utilize macropinocytosis pathway as an entry route into cells 49 . Macropinocytosis is dependent on 122 amiloride-sensitive Na+/H+ exchangers 50 . Upon treatment with Amiloride, we found no alteration in 123 the uptake of RBD, dextran and transferrin confirming that macropinocytosis does not play a role in 124 RBD trafficking in AGS cells ( Figure S2G, S2H) . Together, the co-localization studies and 125 pharmacological inhibition experiments strongly suggest that RBD uptake occurs via the CG Pathway 126 and is inhibited by specific blockers of the CG pathway. 127 

128 Given the relevance of acidification in both formation of CG endosomes 34, 36 and in the context of viral 129 infection 51 , we focused on studying the role of acidification inhibitors on the uptake of RBD. We 130 checked the effect of BafilomycinA1 (BafA1), a specific inhibitor of V-ATPase 52 , on RBD, dextran 131 and transferrin uptake in AGS cells. Treatment with 200nM BafA1 strongly reduced both RBD and 132 dextran uptake ( Figure 1F , 1G) and enhanced the normalized transferrin uptake ( Figure 1H, 1I) . This 133 could be because BafA1 also retards the transferrin recycling from the recycling endosomes 53 and 134 thereby increasing the net amount of transferrin internalized within cells as observed. A dose-dependent 135 reduction in RBD and dextran uptake and an increase in transferrin uptake was seen when cells were 136 treated with a higher concentration of BafA1 ( Figure S3A , S3B (i)). We examined the effect of NH4Cl, 137 a weak base known to alter endosomal acidification 54 , on the uptake of these 3 cargoes. We observed 138 similar results as with BafA1 ( Figure S3A , S3B (i)), thus re-establishing our earlier 34 finding that uptake 139 via the CG pathway is pH sensitive and blocking acidification results in reduced CG uptake. 140 Towards understanding the mechanism of action for acidification inhibitors in bringing about these 141 changes in trafficking, we assessed their effect on two parametersnumbers of endosomes ( Figure S3B 142 (ii)) and per-endosome intensity in the presence/absence of inhibitor ( Figure S3B (iii)). We observed 143 that both BafA1 and NH4Cl reduced the total number of RBD and dextran endosomes without affecting 144 the per-endosome intensity. However, while the total number of transferrin endosomes remained 145 unchanged, the per-endosome intensity of transferrin increased with BafA1 and NH4Cl treatment. This 146 indicates that the reduction in RBD and dextran is likely due to a block in the entry while an increase 147 in per-endosome transferrin intensity could be because of a block in the formation of recycling 148 endosome carriers, as proposed earlier. 149 We studied the effect of BafA1 on RBD uptake in cells overexpressing myc-tagged ACE2 receptor by 150 measuring the uptake of RBD normalized to the surface ACE2 levels. We observed that BafA1 strongly 151 affects the normalized RBD uptake ( Figure S3C , S3D). HEK-293T cells, which is also permissive to 152 Spike-pseudovirus transduction ( Figure S6C ), showed similar inhibition of RBD and dextran uptake, 153 and increase in transferrin uptake with BafA1 (Figure S10A-S10D). 154 RBD is localized to acidic compartments 155 Internalized cargoes can be recycled along with the bulk membrane 55 or directed towards degradation 156 with the fluid phase 56 . Typically, transferrin bound to its receptor marks the early sorting and recycling endosomes and lysotracker labels the acidic degradative compartments within a cell 31 . At 30 minutes 158 of pulse with RBD, dextran and transferrin, while a small fraction of RBD (~36%) associated with 159 transferrin, the majority of RBD (~84%) co-localized with dextran suggesting that RBD is directed 160 predominantly towards the degradation route rather than the recycling route ( Figure 1B, 1C) . The 161 lysotracker labelling showed highly acidic tubular compartments with significant co-localization with 162 RBD. At 30 minutes of pulse with RBD, around 55% of RBD co-localized with lysotracker marked 163 compartments. At longer time points (3 hours) of pulse with RBD, an even increased proportion of RBD 164 (85%) associated with compartments marked by lysotracker, confirming that RBD is trafficked to acidic 165 compartments (Figure 2A, 2B) . 166 BafilomycinA1 and NH4Cl alter the pH of acidic endosomal compartments 167 We next focused on determining the change in endosomal pH brought about by various inhibitors within 168 the acidic compartments populated by RBD. Cells were labelled with pH-sensitive (FITC) and pH-6 insensitive (TMR) dextran for 2 hours and chased for 1 hour with or without inhibitors ( Figure 2C , 170 Methods). The above pulse and chase durations were chosen to allow accumulation of labelled dextran 171 in late endosomes and lysosomal compartments (co-labelled by Lysotracker, data not shown). 172 Additionally, since the acidification inhibitors also have inhibitory roles in the early steps of CG 173 endocytosis as discussed in the previous section, to evaluate their effect on endosomal pH, cells were 174 incubated with inhibitors only during the chase. While the ratio of the fluorescence of these probes is 175 used to estimate endosomal pH by comparing the ratio with the calibration curve 57 ( Figure S4A increasing the pH of these endosomes to 6.6 ( Figure 2D , 2E, S4C). While BafA1 marginally changed 182 the TMR intensity per endosome, NH4Cl greatly increased the TMR intensity indicating that NH4Cl 183 also brings about the fusion of endosomes ( Figure S4D ). All the acidification inhibitors also reduced 184 the numbers of endosomes ( Figure S4D ) and this effect was most prominent with NH4Cl wherein the 185 endosomes were organized close to the perinuclear region ( Figure S4C ). The spatial pH maps show the 186 distribution of pH of endosomes within a cell. Cells treated with BafA1 400nM and NH4Cl showed a 187 homogenous distribution of endosomes with increased pH similar to the respective cell averages. BafA1 188 200nM cells, on the other hand, showed heterogeneity in endosomal pH with some endosomes depicting 189 high pH while others were closer to the average ( Figure 2F ). 190 To assess the effect of BafA1 on the pH of early time point endosomes, AGS cells were labelled with 191 FITC and TMR dextran for 20 minutes and chased for 10 minutes with or without BafA1 for the entire 192 duration of pulse and chase ( Figure S4E ). While the total amount of dextran uptake is not affected 193 significantly, the endosomal FITC intensity and the endosomal ratio of FITC/TMR, which can be 194 considered as a proxy for endosomal pH, show a robust increase with BafA1 treatment ( Figure S4F ). 195 This indicates that BafA1 also affects the endosomal pH of early time point endosomes. 196 Chloroquine treatment does not affect RBD uptake and minimally alters endosomal pH 197 Chloroquine, a diprotic weak base, is expected to accumulate in acidic compartments and neutralize 198 lysosomal pH 58 . While, mounting evidence shows that Chloroquine and its analogs can inhibit the 199 infection by several viruses such as Ebola, Dengue, Chikungunya, HIV, etc 59 , many studies point 200 towards differences between the mode of action of Chloroquine and acidification inhibitors -BafA1 201 and NH4Cl 60,61 . We, therefore, tested the effect of Chloroquine on RBD, dextran and transferrin uptake 202 to verify if it behaves like BafA1. We found that upon treatment with Chloroquine, the uptake of neither 203 RBD nor transferrin was altered significantly ( Figure S5A , S5B). Dextran uptake was marginally higher 204 upon treatment with Chloroquine ( Figure S5B ). 205 The effect of Chloroquine in changing the endosomal pH of late endosomes using FITC/TMR ratio as 206 a proxy for endosomal pH was assessed. At different concentrations of Chloroquine tested, the 207 endosomal pH was only minimally increased ( Figure S5C , S5D). We also observed that both FITC and 208 TMR endosomal intensities increased with the concentration of Chloroquine. To confirm our results, 209 we used another method to estimate endosomal pH. FITC has a pH-sensitive (488nm) and a pH-210 insensitive excitation (450nm) 54 . We used the 488/458 excitation ratio of FITC dextran as a readout of 211 pH and found that this ratio also showed only a small albeit significant increase with Chloroquine when 

If the pseudovirus expressing the full-length spike mimicked the same trafficking pathway for entry as 242 RBD, we reasoned that the transduction efficiency would be reduced upon treatment with inhibitors 243 affecting RBD uptake. SARS-CoV2 Spike-pseudovirus transduction efficiency has been reported to be 244 reduced upon treatment with NH4Cl, BafA1 and Chloroquine 24,64 . However, we wanted to specifically 245 explore the actions of these inhibitors at the initial stages of infection. Therefore, to address this, we 246 pre-treated cells with drugs for an hour followed by the addition of Spike-pseudovirus in the presence 247 of the drug for 2, 4 or 8 hours. Both virus and drug were removed thereafter, and cells were incubated 248 with fresh media either in the absence or presence of a minimal concentration of the drug as indicated 249 ( Figure 3A , Methods). This design was chosen to reduce long-term toxicity of the inhibitors to the cells 250 and minimize any secondary effects on the translational processes of the reporter gene post entry. 251 Infection, or transduction efficiency, is reported as the normalized percentage of transduction compared 252 to corresponding control and cell viability is measured in terms of nuclei number normalized to control. 253 We tested the effect of NH4Cl and BafA1 on the Spike-pseudovirus transduction assay in AGS cells Esomeprazole, Pantoprazole, SCH-28080, Lansoprazole) and a protonophore that disrupts proton 288 gradient (Niclosamide). We developed a quantitative high throughput screening pipeline for testing 289 these drugs in both endocytic assay as well as pH estimation assay in AGS cells. The screen was carried 290 out at a concentration of 10µM for all drugs. 291 Of the 6 drugs tested in the endocytosis assay, Niclosamide showed the strongest effect on the uptake 292 of the 3 probes (RBD, dextran and transferrin) similar to what we observed for acidification inhibitors. 293 Niclosamide treated cells showed reduced RBD and dextran uptake and increased transferrin uptake 294 ( Figure 4B , 4C). It is interesting to note that while the other proton pump inhibitors had minimal effects 295 on RBD or dextran uptake at the concentration tested, Omeprazole and Pantoprazole showed a 296 significant increase in transferrin uptake ( Figure 4C , S7A). This suggests that these two drugs could 297 9 specifically act on the transferrin containing endosomes and not in the compartments of relevance for 298 RBD and dextran uptake, while Niclosamide inhibits the RBD and dextran uptake. 299 Of the 6 drugs tested in the late endosomal pH estimation assay, Niclosamide also showed the strongest 300 neutralization effect on the pH of acidic endosomes ( Figure 4E ) by increasing the endosomal ratio of 301 FITC/TMR ( Figure S7C ). The other drugs had minimal effects on the pH of late endosomes at the 302 concentration tested ( Figure 5E , S7B). The spatial pH maps of Niclosamide treated cells show an 303 increase in pH in the majority of endosomes within the cell ( Figure 5D ). Niclosamide increased the 304 FITC endosomal intensity and reduced the numbers of endosomes ( Figure S7C ) similar to the effect of 305 BafA1 on these endosomal trafficking parameters. 306 Omeprazole and other proton pump inhibitors are prodrugs which are used for treating Gastro- pseudovirus is also dependent on endosomal acidification. Further, by employing a targeted drug screen, 383 we have identified Niclosamide as a potential inhibitor against SARS-CoV2 entry (Figure 6 ). 384 The choice of viral entry into host cells is influenced by cell surface interacting partners and co-factors 423 Surprisingly, Chloroquine did not affect RBD uptake and only marginally raised the endosomal pH. 424 However, it caused a strong inhibition of Spike-pseudovirus infection. This strongly suggests that 425 Chloroquine could be operating in the initial steps of viral infection but post endocytosis 64 , as observed 12 with RBD uptake. Chloroquine is likely to function in many pH-independent ways to inhibit SARS-427 CoV2 infections, distinct from Niclosamide. For example, by altering terminal glycosylation of ACE2 428 86 ; via its activity as a zinc ionophore affecting ACE2 activation 87,88 ; by interacting with ER resident 429 Sigma receptors that initiates cell stress response 89 ; by its ability to strongly bind a viral protease 430 essential for Spike activation 90 . At this time, the exact mechanism(s) by which Chloroquine inhibits 431 SARS-CoV2 entry remains unclear. 432 In conclusion, our study reports the high capacity CG pathway as a potential endocytic route for SARS-433 CoV2. We further show that endosomal acidification is critical for SARS-CoV2 entry and infection and 434 can be a promising therapeutic target as observed by the results seen with Niclosamide, BafilomycinA1 435 and NH4Cl. This study also paves way for large-scale screens to repurpose FDA-approved drugs as Data representation in C and E is as described in Figure 

SARS coronavirus entry into host cells through a novel clathrin-and caveolae-609 independent endocytic pathway

Role of the Spike Glycoprotein of Human Middle 611

East Respiratory Syndrome Coronavirus (MERS-CoV) in Virus Entry and Syncytia Formation

A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals

Inhibition of PIKfyve kinase prevents infection by Zaire ebolavirus and SARS-616

Pathways Function at the Cell Surface

Endocytic pathways and endosomal trafficking: a 620 primer

GPI-anchored proteins are delivered to 622 recycling endosomes via a distinct cdc42-regulated clathrin-independent pinocytic pathway

Structure, function and regulation of the vacuolar (H + )-ATPases

Population distribution analyses reveal a hierarchy of molecular players 627 underlying parallel endocytic pathways

Exploiting cell-to-cell variability to detect cellular perturbations

Arf6-independent GPI-anchored protein-enriched early endosomal 631 compartments fuse with sorting endosomes via a Rab5/phosphatidylinositol-3′-kinase-632 dependent machinery

Small GTPases and BAR domain proteins regulate branched actin 634 polymerisation for clathrin and dynamin-independent endocytosis

Identification of Required Host Factors for SARS-CoV-2 Infection in Human 637 Cells

Adeno-associated virus 2 infection requires endocytosis 639 through the CLIC/GEEC pathway

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: 641 implication for development of RBD protein as a viral attachment inhibitor and vaccine

SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a 644

Serological Assay, Antigen Production, and Test Setup

Small GTPases and BAR domain proteins regulate branched actin 646 polymerisation for clathrin and dynamin-independent endocytosis

Cholesterol-sensitive Cdc42 activation regulates actin polymerization for 648 endocytosis via the GEEC pathway

ARF1 is directly involved in dynamin-independent endocytosis

Analysis of endocytic pathways in Drosophila cells reveals a conserved role 652 for GBF1 in internalization via GEECs

LG186: An Inhibitor of GBF1 Function that Causes Golgi Disassembly in Human 654 18 and Canine Cells

Mechanochemical feedback control of dynamin independent 656 endocytosis modulates membrane tension in adherent cells

Molecular size-fractionation during endocytosis 658 in macrophages

Virus entry by macropinocytosis

An overview of inhibitors of Na+/H+ exchanger

Effect of Bafilomycin A1 and Nocodazole on Endocytic Transport in HeLa 664 Cells: Implications for Viral Uncoating and Infection

A model for the proteolipid ring 666 and bafilomycin/concanamycin-binding site in the vacuolar ATPase of Neurospora crassa

Bafilomycin A1 669 treatment retards transferrin receptor recycling more than bulk membrane recycling

Fluorescence probe measurement of the intralysosomal pH in living 672 cells and the perturbation of pH by various agents

Sorting of membrane components from endosomes 674 and subsequent recycling to the cell surface occurs by a bulk flow process

Iterative fractionation of recycling receptors 677 from lysosomally destined ligands in an early sorting endosome

Endosome pH measured in single cells by dual 680 fluorescence flow cytometry: rapid acidification of insulin to pH 6

pH and the anti-683 malarial action of chloroquine

Chloroquine, a FDA-approved Drug, Prevents Zika Virus Infection and its 685

Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome 687 fusion

Lysosomal adaptation: How cells 689 19 respond to lysosomotropic compounds

Protocol and reagents for pseudotyping lentiviral particles with SARS-691

CoV-2 spike protein for neutralization assays

Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2

Remdesivir and chloroquine effectively inhibit the recently emerged novel 695 coronavirus (2019-nCoV) in vitro

Pharmacokinetics and pharmacodynamics of the proton pump inhibitors

Chemistry of covalent inhibition of the gastric

ATPase by proton pump inhibitors

H+-ATPases of renal cortical and 701 medullary endosomes are differentially sensitive to Sch-28080 and omeprazole

A Rationale for the Use of Proton Pump Inhibitors 704 as Antineoplastic Agents

Inhibition of endosomal sequestration of basic anticancer drugs: 706 Influence on cytotoxicity and tissue penetration

Influence of the proton pump inhibitor lansoprazole 708 on distribution and activity of doxorubicin in solid tumors

Use of the Proton Pump Inhibitor Pantoprazole to 710

Modify the Distribution and Activity of Doxorubicin: A Potential Strategy to Improve the 711 Therapy of Solid Tumors

Niclosamide Is a Proton Carrier and Targets Acidic Endosomes with Broad 713

Neutralization of Acidic Intracellular Vesicles by Niclosamide Inhibits Multiple 715 Steps of the Dengue Virus Life Cycle In Vitro

Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin 717 in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, 718 phase 2 trial

Beyond an antihelminthic 720 drug

Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in 722 ovarian cancer

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting 724 SARS-CoV-2 infection in vitro

Genetic screens identify host factors for SARS-CoV-2 and common cold 726 coronaviruses

Cholesterol-sensitive Cdc42 activation regulates actin polymerization for 728 endocytosis via the GEEC pathway

Niclosamide induces mitochondria 730 fragmentation and promotes both apoptotic and autophagic cell death

Inhibition of severe acute respiratory syndrome coronavirus replication by 733 niclosamide

Screening of FDA-approved drugs using a MERS-CoV clinical isolate from South 735 Korea identifies potential therapeutic options for COVID-19

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-738 approved drugs

Antiviral therapies against Ebola 740 and other emerging viral diseases using existing medicines that block virus entry

SARS-CoV-2 and SARS-CoV differ in their cell tropism and drug sensitivity 743 profiles

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread

ACE2: From vasopeptidase to SARS virus receptor

Zinc(II)-The Overlooked Éminence Grise of Chloroquine's Fight against 749 COVID-19?

A SARS-CoV-2 protein interaction map reveals targets for drug 751 repurposing

In silico study of azithromycin, chloroquine and hydroxychloroquine and 753 their potential mechanisms of action against SARS-CoV-2 infection

Image co-localization-co-occurrence versus 756 correlation

We thank Nevan Krogan (UCSF, USA) for Spike expression construct

USA) for secreted RBD expression construct, Biocon, Ltd (India) and Raghavan Varadharajan (IISc

India) for providing purified RBD for initial experiments, Minhaj Sirajuddin (inSTEM, India) for 762 mCherry expression plasmid

A. RBD Lysotracker Merge